4//SEC Filing
Astor Andrew 4
Accession 0000914190-21-000282
CIK 0001196298other
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 6:08 PM ET
Size
17.3 KB
Accession
0000914190-21-000282
Insider Transaction Report
Form 4
NEPHROS INCNEPH
Astor Andrew
Chief Financial Officer
Transactions
- Purchase
Common Stock
2021-08-17$7.67/sh+2,500$19,172→ 75,458 total - Purchase
Common Stock
2021-08-18$7.77/sh+2,500$19,433→ 77,958 total
Holdings
- 14,815
Warrants (right to buy)
Exercise: $2.70From: 2017-03-17Exp: 2022-03-17→ Common Stock (14,815 underlying) - 64,399
Stock Option (right to buy)
Exercise: $4.14Exp: 2027-02-13→ Common Stock (64,399 underlying) - 46,525
Stock Option (right to buy)
Exercise: $2.64Exp: 2027-05-01→ Common Stock (46,525 underlying) - 5,556
Stock Option (right to buy)
Exercise: $4.50Exp: 2027-12-20→ Common Stock (5,556 underlying) - 22,223
Stock Option (right to buy)
Exercise: $5.85Exp: 2028-12-19→ Common Stock (22,223 underlying) - 152,064
Stock Option (right to buy)
Exercise: $7.07Exp: 2030-08-24→ Common Stock (152,064 underlying) - 20,000
Stock Option (right to buy)
Exercise: $8.30Exp: 2029-12-16→ Common Stock (20,000 underlying)
Footnotes (8)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.66 to $7.6699. The reporting person undertakes to provide the Company, any security holder of the Company. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.60 to $7.85. The reporting person undertakes to provide the Company, any security holder of the Company. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]On 2/13/17, the Reporting Person was granted an option to purchase 64,399 shares of common stock of the Company. Options to purchase 8,049 shares vested on 2/13/18; options to purchase 24,150 shares vest quarterly in 12 equal amounts commencing on 5/13/18; and options to purchase 32,200 shares vested upon achievement of previously disclosed performance measures.
- [F4]On 5/1/17, the Reporting Person was granted an option to purchase 46,525 shares of common stock of the Company. Options to purchase 5,815 shares vested on 5/1/18; options to purchase 17,447 shares vest quarterly in 12 equal amounts commencing on 7/1/18; and options to purchase 23,263 shares vested upon achievement of previously disclosed performance measures.
- [F5]On 12/20/17, the Reporting Person was granted an option to purchase 5,556 shares of common stock of the Company. Options to purchase 1,389 shares vested on 12/20/18 and options to purchase 4,167 shares vest quarterly in 12 equal amounts commencing on 3/20/19.
- [F6]On 12/19/18, the Reporting Person was granted an option to purchase 22,223 shares of common stock of the Company. Options to purchase 5,555 shares vested on 12/19/19 and options to purchase 16,668 shares vest quarterly in 12 equal amounts commencing on 3/19/20.
- [F7]On 12/16/19, the Reporting Person was granted an option to purchase 20,000 shares of common stock of the Company. Options to purchase 5,000 shares vest on 12/16/20 and options to purchase 15,000 shares vest quarterly in 12 equal amounts commencing on 3/16/21.
- [F8]On 8/24/20, the Reporting Person was granted an option to purchase 152,064 shares of common stock of the Company. Options to purchase 38,016 shares vest on 8/24/21 and options to purchase 114,048 shares vest quarterly in 12 equal amounts commencing on 11/24/21.
Documents
Issuer
NEPHROS INC
CIK 0001196298
Entity typeother
Related Parties
1- filerCIK 0001698052
Filing Metadata
- Form type
- 4
- Filed
- Aug 17, 8:00 PM ET
- Accepted
- Aug 18, 6:08 PM ET
- Size
- 17.3 KB